The trial attained each its primary endpoints, with semaglutide two.four mg demonstrating statistically sizeable and remarkable improvements in liver fibrosis without having worsening of steatohepatitis, together with resolution of steatohepatitis without having worsening of liver fibrosis in people with MASH in comparison to placebo.1Mumsnet has n